TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05025605
Drug: Placebo Film
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Sublingual Placebo film
Study: NCT05025605
Drug: BXCL501 120 Micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual film containing 120 Micrograms BXCL501
Study: NCT05025605
Drug: BXCL501 60 Micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual film containing 60 Micrograms BXCL501 Europe Only
Study: NCT05730478
Drug: Glaucoma therapy
Normalized name: Sympathomimetics in glaucoma therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASOCT and UBM parameters Comparison
Study: NCT05730478
Drug: Glaucoma therapy
Normalized name: Sympathomimetics in glaucoma therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison
Study: NCT05486065
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Semaglutide placebo s.c. injection once-weekly for 40 weeks. Dose gradually increased over 24 weeks, followed by a 16 week maintenance period.
Study: NCT04875754
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular injection
Study: NCT06380907
Drug: ZL-1102 1% w/w gel BID for 16 weeks
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZL-1102~1% w/w gel BID for 16 weeks
Study: NCT06380907
Drug: ZL-1102 3% w/w gel BID for 16 weeks
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZL-1102 3% w/w gel BID for 16 weeks
Study: NCT06380907
Drug: ZL-1102 3% w/w gel QD for 16 weeks
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZL-1102 3% w/w gel QD for 16 weeks
Study: NCT06380907
Drug: Placebo ZL-1102 0% w/w gel BID for 16 weeks
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle 0% w/w gel BID for 16 weeks
Study: NCT06380907
Drug: Placebo ZL-1102 0% w/w gel QD for 16 weeks
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle 0% w/w gel QD for 16 weeks
Study: NCT05178654
Drug: [14C]PF-07321332
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of 300 mg \[14C\]PF-07321332 containing approximately 100 µCi \[14C\]PF-07321332 coadministered with 100 mg ritonavir.
Study: NCT06255626
Drug: CD40.RBDv vaccin (SARS-Cov2 Vaccin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 or 2 injection(s) of CD40.RBDv vaccine (or mRNA vaccine 1 injection (5:1))
Study: NCT05428670
Drug: RCHOP/RCDOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: RCHOP/RCDOP is the classic treatment of diffuse large B cell lymphoma.
Study: NCT05376969
Drug: DWP16001
Approvals — FDA: no, EMA: no, PMDA: no
Description: DWP16001 Tablets
Study: NCT05120297
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive placebo subcutaneous injection at week 0 and week 4, and will follow up to week 16.
Study: NCT05175001
Drug: Diprospan
Normalized name: Irospan Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diprospan combined with ropivacaine in ultrasound-guided thoracic paravertebral nerve block
Study: NCT05388825
Drug: TPN171H 2.5mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPN171H 2.5mg is recommended to take warm water on an empty stomach (2 hours or more after dinner)
Study: NCT05388825
Drug: TPN171H 5mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPN171H 5mg is recommended to take warm water on an empty stomach (2 hours or more after dinner)
Study: NCT05388825
Drug: TPN171H 10mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPN171H 10mg is recommended to take warm water on an empty stomach (2 hours or more after dinner)
Study: NCT05388825
Drug: Placebo 5mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 5mg is recommended to take warm water on an empty stomach (2 hours or more after dinner)
Study: NCT05388825
Drug: Placebo 10mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 10mg is recommended to take warm water on an empty stomach (2 hours or more after dinner)
Study: NCT06044623
Drug: CDK 4/6 inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Either Palbociclib, Ribociclib or Abemaciclib
Study: NCT06044623
Drug: Endocrine therapy
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Either Letrozole, Anastrozole, Exemestane or Fulvestrant in combination with CDK 4/6-inhibitor
Study: NCT04907539
Drug: RXC004
Approvals — FDA: no, EMA: no, PMDA: no
Description: RXC004 will be administered orally, 2 mg QD (Monotherapy); and 1.5 mg QD (Combination therapy)~Dose Formulation: 0.5 mg or 1 mg capsules.
Study: NCT06640582
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide will be administered as an intravenous (IV) infusion for two days.
Study: NCT06642961
Drug: GR1802 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: GR1802 will be administered SC.
Study: NCT05870111
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo capsule daily for 4 weeks, matched in appearance to citicoline to preserve double-blind, administered orally
Study: NCT05059626
Drug: simvastatin 10mg
Normalized name: SIMVASTATIN 10MG TAB
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastation acts as a systemic LOX inhibitor.
Study: NCT05526157
Drug: Non-steroidal mineral corticoid receptor antagonists (nsMRA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retrospective analysis using secondary data collection from various sources
Study: NCT04989218
Drug: Novel combination of chemotherapy and immunotherapy
Normalized name: Betagen brand of Betamethasone and Gentamicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is a study of the combination of platinum based chemotherapy (gemcitabine and cisplatin) and doublet immunotherapy (durvalumab and tremelimumab) in the preoperative setting for intrahepatic cholangiocarcinoma with high risk features. Gemcitabine and cisplatin are chemotherapy agents used in the management of locally advanced and metastatic cholangiocarcinoma. Durvalumab is a programmed cell death ligand 1 (PDL1) blocking antibody, that improves the immune response against cancer. Tremelimumab is an antibody that targets cytotoxic T cell lymphocyte-associated protein 4 (CTLA4) on regulatory T cells. It also improves the immune response against cancer cells
Study: NCT04725188
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline IV infusion Q3W up to approximately 2 years
Study: NCT06148948
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching BI 1584862
Study: NCT05557292
Drug: RMC-5552
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT06169579
Drug: ND-003 tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: ND-003 tablets will be administered orally and observe 4 days, and followed by over continuous 28-days cycles.
Study: NCT06169579
Drug: ND-003 tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: ND-003 tablets will be administered orally over continuous 28-days cycles.
Study: NCT06402136
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04918771
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration - not with food. Placebo using Raphamin scheme.
Study: NCT04551053
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo will be administered QD orally
Study: NCT05584631
Drug: Intravenous immune globulin G
Normalized name: GLOBULIN,IMMUNE (IV)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immune globulin G dosed based on the subjects's current dose received for the treatment of CIDP.
Study: NCT05584631
Drug: Subcutaneous immune globulin G
Normalized name: immune globulin subcutaneous (human)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous immune globulin G converted from the subject's current IVIG dose 1:1.
Study: NCT05059522
Drug: Lorlatanib
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT05059522
Drug: CMP 001
Approvals — FDA: no, EMA: no, PMDA: no
Description: IT (intratumoral) or SC (subcutaneous)
Study: NCT05059522
Drug: PF04518600
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion
Study: NCT05177328
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phosphate buffered saline and glycerol
Study: NCT06678581
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solid Oral Tablet
Study: NCT06682000
Drug: DWC202404, DWC202314
Approvals — FDA: no, EMA: no, PMDA: no
Description: - 2 tablet, Oral, Once a day
Study: NCT06682000
Drug: DWC202404, DWC202314P
Approvals — FDA: no, EMA: no, PMDA: no
Description: - 2 tablet, Oral, Once a day
Study: NCT06694480
Drug: FID-022
Approvals — FDA: no, EMA: no, PMDA: no
Description: Advanced solid tumors
Study: NCT06687421
Drug: Androgen deprivation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: GnRH agonist + abiraterone acetate/enzalutamide and/or docetaxel
Study: NCT06686472
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The composition of the placebo is identical to the active formulation except for the exclusion of the active ingredient.
Study: NCT06694740
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients randomized to the placebo arm will receive saline injectable solution. Subcutaneous injection every 24 hours for 3 consecutive days (3 total injections)
Study: NCT05856630
Drug: Zoladex 10.8 MG Drug Implant
Normalized name: Zoladex 10.8 MG Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10.8mg, Single dose, subcutaneously（SC）
Study: NCT06693973
Drug: AcNK-Sup003 cell injection solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: The AcNK technology has successfully achieved the direct, covalent, and directional conjugation of intact antibodies which includes the Fc domain to the surface of NK cells via a one-step enzymatic reaction. This novel approach yields a non-genetically modified NK cell that is conjugated with dual-targeting antibodies, referred to as AcNK. Specifically, AcNK-Sup003 cells are cryopreserved NK cells that have been conjugated with bispecific antibodies target both CD20 and CD19.
Study: NCT06359626
Drug: YHP2205
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test drug: YHP2205
Study: NCT06359626
Drug: YHR2401
Approvals — FDA: no, EMA: no, PMDA: no
Description: comparator: YHR2401
Study: NCT05918146
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline injection plus physical therapy
Study: NCT05691829
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered alongside pembrolizumab every 3 weeks for 6 cycles per institutional standard of care. For non-squamous, the standard chemotherapy option of choice is carboplatin and pemetrexed. For squamous cell carcinoma, the chemotherapy used would be carboplatin and paclitaxel or nab-paclitaxel
Study: NCT04818177
Drug: Institutional standard intravenous immune globulin treatment
Normalized name: GLOBULIN,IMMUNE (IV)
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatments will be prospectively assigned. Subjects will receive their standard intravenous immune globulin doses. We will measure body composition and identify the relationship between body composition and intravenous immune globulin disposition.
Study: NCT04744831
Drug: DS-8201a 5.4 mg/kg Q3W
Approvals — FDA: no, EMA: no, PMDA: no
Description: DS-8201a for injection will be administered intravenously (IV) at a dose of 5.4 mg/kg every 3 weeks (Q3W)
Study: NCT04744831
Drug: DS-8201a 6.4 mg/kg Q3W
Approvals — FDA: no, EMA: no, PMDA: no
Description: DS-8201a for injection will be administered intravenously (IV) at a dose of 6.4 mg/kg every 3 weeks (Q3W)
Study: NCT05063136
Drug: Capecitabine+endocrine therapy
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine (500mg, tid) (for 1 year)+ standard endocrine therapy (at least 5 years)
Study: NCT05063136
Drug: Placebo+endocrine therapy
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (tid) (for 1 year)+ standard endocrine therapy (at least 5 years)
Study: NCT05654181
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching active drug administered orally
Study: NCT06375564
Drug: 177Lu-AB-3PRGD2 radioligand therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radioligand therapy using 177Lu-AB-3PRGD2 80 mCi (2.96 GBq) will be performed 6-weekly. A maximum of 4 cycles will be administered.
Study: NCT05913180
Drug: Ascorbic Acid 1000 MG
Normalized name: ascorbic acid 1000 MG
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1000mg Ascorbic acid orally daily started on the day of elective gynecological surgery for 10 days
Study: NCT05913180
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet daily starting day of elective gynecological surgery for 10 days
Study: NCT05502900
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: White round tablets, each with a dose of 5 mg Melatonin. 4 tablets taken simultaneously at night. Tablets can be crushed and/or taken with a glass of water if the patient wish.
Study: NCT04839926
Drug: 0.5mg CY150112
Approvals — FDA: no, EMA: no, PMDA: no
Description: single oral CY150112 while fasting on day 1.
Study: NCT04839926
Drug: 1.5mg CY150112
Approvals — FDA: no, EMA: no, PMDA: no
Description: single oral CY150112 while fasting on day 1.
Study: NCT04839926
Drug: 4.5mg CY150112
Approvals — FDA: no, EMA: no, PMDA: no
Description: single oral CY150112 while fasting on day 1.
Study: NCT04839926
Drug: 10mg CY150112
Approvals — FDA: no, EMA: no, PMDA: no
Description: single oral CY150112 while fasting on day 1.
Study: NCT04839926
Drug: 18mg CY150112
Approvals — FDA: no, EMA: no, PMDA: no
Description: single oral CY150112 while fasting on day 1.
Study: NCT04839926
Drug: 24mg CY150112
Approvals — FDA: no, EMA: no, PMDA: no
Description: single oral CY150112 while fasting on day 1.
Study: NCT06160778
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous normal saline placebo (labelled as morphine) given at 0.1 mg/kg of body weight up to a maximum of 5 mg in a single dose.
Study: NCT06160778
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous normal saline placebo (labelled as ketorolac) given at 0.5 mg/kg of body weight up to a maximum of 30 mg in a single dose.
Study: NCT04658680
Drug: BCG vaccination at first health facility contact
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal injection at first health facility contact: 0.05 ml dose Mycobacterium bovis BCG live attenuated vaccine in the left deltoid region.~The strain supplied by the national vaccination programme is provided through UNICEF. Different strains are used interchangeably. The additional BCG vaccines provided through this study will be procured by the Bandim Health Project. Vaccines will be from the WHO list of prequalified vaccines and the same strain will be used in intervention and control health centres.
Study: NCT05657171
Drug: cyproterone Acetate/Ethinyl Estradiol Combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: cyproterone acetate (CPA) 2 mg, combined with EE 35 µg.
Study: NCT06370663
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (Gesitabine)
Study: NCT05642845
Drug: Liprimar® film-coated tablet 40 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liprimar® is manufactured by Pfizer Pharmaceuticals LLC, Puerto Rico, LLC Polysan Scientific and Technological Pharmaceutical Firm; RU holder: Pfizer Inc, USA. Each tablet contains 40 mg of atorvastatin.
Study: NCT06636825
Drug: Caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 400 mg caffeine capsule taken in a single dose 1 hour prior to graded hypercapnia
Study: NCT06636825
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (microcrystalline cellulose) capsule taken in a single dose 1 hour prior to graded hypercapnia
Study: NCT06170242
Drug: EDP-323 Dose Regimen 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: EDP-323 capsule
Study: NCT06170242
Drug: EDP-323 Dose Regimen 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: EDP-323 capsule
Study: NCT06170242
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule
Study: NCT05917964
Drug: LP-168 tablet
Normalized name: LP-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: LP-168 is a small molecule kinase inhibitor that is administered once daily via oral administration
Study: NCT05901779
Drug: live combined Bifidobacteriun, Lactobacillus and Enterococcus capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotics capsules containing Bifidobacterium longum, Lactobacillus acidophilus, and Enterococcus faecalis. Each capsule contained\>10,000,000 colony-forming units (CFUs). This drug can treat endoxemia caused by imbalance of intestinal flora.
Study: NCT05746273
Drug: Transdermal Placebo Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will wear placebo transdermal patches daily for 12-15 weeks. They will apply a study patch each morning and remove at bedtime. Placebo patch dose will titrate up from 3.5mg to 7mg, and then can optionally be further titrated to a maximum dose of 14mg. After week12, the dose will be slowly tapered over 2-3 weeks.
Study: NCT05960201
Drug: [18F]fluoroestradiol (FES)
Approvals — FDA: no, EMA: no, PMDA: no
Description: F-18 FES 111\~222 MBq(megabecquerel) injection
Study: NCT06137092
Drug: Factor VIII, recombinant human with Fc fusion (rFVIII-Fc)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rFVIII-Fc, IV, 50 units/kg/ single dose, cross-over
Study: NCT06410131
Drug: FTL008.16
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion every 2 weeks
Study: NCT06468943
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 750mg/㎡/21d（d1） Intravenous infusion
Study: NCT06468943
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50mg/㎡/21d（d1） Intravenous infusion
Study: NCT04722679
Drug: Non-VKA Oral Anticoagulants (NOAC)
Normalized name: Tavist Non-Sedating Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Follow clinical practice.
Study: NCT05013905
Drug: PRA023 IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRA023 administered at timepoints as directed by the protocol
Study: NCT05607589
Drug: DWP213388
Approvals — FDA: no, EMA: no, PMDA: no
Description: immunosuppressant
Study: NCT05360602
Drug: The standard care for post-PCI MI
Approvals — FDA: no, EMA: no, PMDA: no
Description: will include the required antiplatelet (Dual Antiplatelet Therapy; DAPT), anticoagulants, and anti-ischemic measures (high-intensity statin, ACEI, or aldosterone) as per latest guidelines recommendations.
Study: NCT06255340
Drug: Placebo matching BI 3031185
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT06491576
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: taking the placebo orally
Study: NCT04380740
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: During the extended dosing of abatacept, those randomized to receive 4 doses will receive a placebo consisting of an equal volume of normal saline solution.
Study: NCT06644404
Drug: DWP16001 0.3mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet, Orally, Once daily single dose
Study: NCT06644404
Drug: DWC202407 1,000mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet, Orally, Twice daily
Study: NCT06644404
Drug: DWC202408 2mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet, Orally, Once daily single dose
Study: NCT06253611
Drug: FOLFOX regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxaliplatin 85 mg/m², leucovorin 400 mg/m², bolus of 5-FU 400 mg/m², continuous 5-FU 2400/m² in 46 hours; every 2 weeks
Study: NCT06674291
Drug: No intervention (observational study)
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is an observational registry conducted in the real world clinical setting and there is no intervention in this study. Treatment of MDR-END Regimen and the follow-up of subjects will be conducted in the clinical judgment of the investigator.
Study: NCT03261375
Drug: Antihypertensive Agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium channel blocker, Diuretic
Study: NCT06570811
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets is supplied to breast cancer patients who receive 80 mg/ m2 paclitaxel (taxol®) chemotherapy.
Study: NCT06570811
Drug: Coenzyme Q10 200mg twice daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg daily (200mg twice daily) of Coenzyme Q10 (an antioxidant that's in many foods, and it's made naturally in the investigator's bodies) is supplied to breast cancer patients who receive 80 mg/ m2 paclitaxel (taxol®) chemotherapy.
Study: NCT06376110
Drug: Topical Antioxidant Serum
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: An oil-free vitamin C serum for oily skin and blemish-prone skin that delivers advanced environmental protection, reduces oiliness, refines skin texture, and visibly improves skin clarity and fine lines.
Study: NCT05411900
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will consist of equal volume of saline solution (0.9%). Injections will be repeated at sites 1-1.5 cm apart (0.1 ml, 16.6 units per site), up to 20 sites (333 units).~To reduce pain caused by the injection, lidocaine and prilocaine cream will be applied to the skin area 60 min before the procedure. Additionally, ice could be applied for a few seconds (4-8) before each injection.~Injections will be repeated at week 0 and week 12.~The active treatment and placebo solutions will be transparent and indistinguishable to maintain treatment blindness.
Study: NCT06635850
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo for inhalation
Study: NCT06293287
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo (0.9% saline solution)
Study: NCT05451329
Drug: VVN539 Ophthalmic Solution 0.02%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once a day \[q.d.\] in the morning, q.d. in the evening and twice a day \[b.i.d.\]) will be tested for 7-9 days
Study: NCT05451329
Drug: VVN539 Ophthalmic Solution 0.04%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once a day \[q.d.\] in the morning, q.d. in the evening and twice a day \[b.i.d.\]) will be tested for 7-9 days
Study: NCT05451329
Drug: VVN539 Ophthalmic Solution Vehicle
Normalized name: Neisseria meningitidis group B strain NZ98/254 outer membrane vesicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once a day \[q.d.\] in the morning, q.d. in the evening and twice a day \[b.i.d.\]) will be tested for 7-9 days
Study: NCT05611957
Drug: LY3437943
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC.